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Over 20 years have passed since the first experimental obser-
vations on altered drug transport were made in anthracycline
resistant tumour cells (Kessel et al., 1968). The identification
of a surface glycoprotein - which subsequently became
known as P glycoprotein (P-gp) - as a key feature in drug
efflux was made as long ago as 1976 (Juliano & Ling, 1976).
This has been followed by a remarkable expansion of know-
ledge, particularly at the genetic level, which has provided
fascinating insights into the experimental observations of
cross-resistance among certain agents (so-called 'multi-drug
resistance'). The main hypothesis, that the resistant cell over
expresses an energy dependent membrane-bound efflux pump
(P-gp) protecting it from toxic natural products,-has proved
particularly attractive to clinicians (Rothenberg & Ling,
1989). The notion that this may be reversed by specific
membrane active non-cytotoxic agents, as has been demon-
strated in vitro, is especially appealing, the more so since the
importance of drug resistance as a major problem in clinical
management is increasingly recognised. Once the coding
sequence or mdrl mRNA (whose encoded product in humans
is P-gp) was known (Ueda et al., 1987), the tools were
available to make detailed assessments of clinical material for
mdrl gene expression. The development of relatively specific
monoclonal antibodies, together with the ultra-sensitive poly-
merase chain reaction (pcr) technique has led to a further
expansion of information on P-gp expression (Noonan et al.,
1990) in human cancer. What can we now conclude therefore
about the therapeutic importance of these observations? In
attempting to answer this question, a number of factors now
need to be considered, and these are likely to temper the
enthusiasm of the clinician impatient for rapid improvements
in treatment.
Firstly, it is clear that the mdrl gene product (P-gp) is
expressed in a large range of normal tissues as well as
tumours. Recent data indicate these should include normal
haemopoietic progenitor cells (Chaudhary & Roninson, 1991)
as well as cells lining biliary canaliculi in the liver, cells lining
the mucosal surface of the jejunum and colon, cells on the
apical epithelial surface of the proximal tubule in the kidney,
cells lining capiliary endothelia in the brain and testis, and
several others (Cordon-Cardo et al., 1990). Moreover, within
tumours themselves, non-malignant stromal cells may express
P-gp, to an extent which may exceed that of the malignant
components.
Secondly, data are now emerging which suggest that P-gp
may have biological functions in cancer cells in addition to
those involved in cytotoxic drug transport. These functions
appear to involve the ability of cancer cells to invade and
metastasise. A study in colon cancer (Weinstein et al., 1991)
has indicated increased numbers of P-gp positive cells at the
invading edges of tumours of high metastatic potential. This
association between level of expression of P-glycoprotein and
the metastatic potential (of an untreated experimental rat
liver tumour) has recently been confirmed by Ling and co-
workers (Bradley et al., 1992). Their data add support to the
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view that the mechanism whereby P-gp-overexpression influ-
ences disease progression may be quite unrelated to any
exposure to cytotoxic drugs.
Clearly these observations have to be borne in mind when
retrospective correlations are drawn between P-gp positivity
in tumour specimens and subsequent treatment outcome (as
in childhood sarcoma (Chan et al., 1990), neuroblastoma
(Chan et al., 1991), breast cancer (Verelle et al., 1991) and
leukaemia (Pirker et al., 1991)). Most recently, correlations
have been drawn between treatment response and pcr-
detected MDR-1 expression in two further solid tumours -
small cell lung cancer and ovarian cancer (Holzmayer et al.,
1992). In this study, a failure to respond to treatment was
seen significantly more frequently in MDR 1-positive cases,
and interestingly this did seem to be more apparent when
treatment included 'MDR' drugs, although the number of
cases (24 in all) was very small. However, to assume, in each
of these studies, that the positive correlates which have been
seen relate to drug resistance is to ignore other explanations,
such as the possibility that P-gyp expression itselfcan directly
or indirectly lead to a more aggressive pattern of tumour
behaviour. Hypotheses which could explain how this might
arise, based on alterations in cell - cell adhesion and enhanc-
ed tumour cell motility (Weinstein et al., 1989), are testable,
and they may or may not be related to the property of P-gp
- clearly demonstrated at least experimentally - to function
as part of a specific drug resistance mechanism.
Thirdly, the use of modulators of P-gp cannot be critically
assessed without taking into account the effect which these
agents, if introduced at truly biologically effective concentra-
tions, may have on normal physiological processes in which
P-gp may play a part. These include biliary and renal routes
for cytotoxic drug clearance, and in both these cases the
effective blockade of the function of normal P-gp could have
a significant impact on drug handling, the end result being
far more critical than any effect on cellular drug transport at
the level of a notionally P-gp positive resistant tumour cell.
Other effects, such as those on renal and hepatic blood flow,
may also be relevant. Such interactions have already been
described in the cases of verapamil (Kerr et al., 1986) and
cyclosporin A (Lum et al., 1992) and probably will be
observed more frequently in future trials using more effective
P-gp modulators.
Fourthly, it is increasingly being accepted that enhanced
P-gp expression is likely to be accompanied by elevated
expression of other genes which might relate to drug resis-
tance, and that modulation will have to take account of the
multi-factorial nature ofclinical drug resistance. The problem
is that no other mechanism has been as well characterised
and identified as has the P-gp mechanism ('classical' multi-
drug resistance), in tissue culture models. However, other
possibilities exist for mechanisms which might underly resis-
tance to natural products; these include defective topoiso-
merase II expression (Beck et al., 1987), and further studies
of this are clearly indicated.
Given all these caveats, is it still possible to sustain the
case for initiating further clinical work based on P-gp as a
target for resistance modulation? The answer is a qualified
yes - but in certain areas only. A range of new modulators
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with the potential for greater selectivity are now available,
and clinical trials to examine their therapeutic efficacy can be
conducted in different ways. Firstly it is highly desirable to
carry out initial pharmacokinetic studies to assess the likely
interaction between modulators, when given at a biologically
effective dose, and the cytotoxic agent. Next, a variety of
strategies can be adopted. Patients with drug refractory
disease can be retreated with the same treatment combined
with a modulator, preferably supported by data on P-gp
expression. In this case it is essential that patients are treated
with precisely the same cytotoxic treatment regimes (includ-
ing continuous infusion schedules) to which they have pre-
viously been exposed and shown to be resistant. A number of
trials using this design have been published and in some cases
their interpretation is difficult because these criteria have not
fully been met (Miller et al., 1991). Most convincing has been
a recently published study using cyclosporin in relapsed mye-
loma (Sonneveld et al., 1992). Here the evidence of a real
therapeutic gain in refractory patients is persuasive, although
the impact of the overall pharmacokinetic interaction
between cyclosporin and the cytotoxic agents used is still
difficult to assess.
An alternative trial design is the use of modulators in the
treatment of tumours known to be intrinsically resistant, e.g.
renal and colon cancer, with generally high levels of P-gp
expression. Such trials may be non-randomised and can
incorporate a modulator as part of the initial therapy. To
date one such study has been reported as negative (Roden-
burg et al., 1991), suggesting that in these cases resistance to
drugs such as the anthracyclines and vinca alkaloids is a
more complex phenomenon. However further studies should
be completed before firm conclusions can be drawn.
A third option is to perform randomised trials in pre-
viously untreated patients, with tumour types in which it is a
reasonable assumption that a number of cases will contain a
proportion of P-gp positive cells e.g. breast cancer and
myeloma. The disadvantage of such trials is that they require
to be of a relatively large size in order to detect differences in
treatment outcome (response or survival) which can be attri-
buted to the addition of a modulator to the initial chemo-
therapy regime. Such studies are already underway, and the
results will be important in helping to formulate definitive
views on the overall importance of P-gp modulations.
At present it would seem sensible to limit new modulator
studies to certain key clinical areas, specifically myeloma,
leukaemia and lymphoma in which preliminary results have
been positive (Miller et al., 1991; Sonneveld et al., 1992;
Sonneveld & Nooter, 1990). Notwithstanding the caveats pre-
viously discussed, further information to clarify the role of
modulators in these areas would be useful. Meanwhile, it
should also be remembered that circumvention of P gp-medi-
ated drug resistance can clearly be achieved experimentally,
and perhaps clinically, be a different means, i.e. the use of
non-cross resistant cytotoxic agents. These include the mor-
pholinyl anthracyclines (Coley et al., 1989) and also rhizoxin
(Tsuruo et al., 1986), and clinical trials of these agents are
now underway (Bissett et al., 1992).
In summary, it seems quite likely that the focus of research
interest in P-gp will shift in future years. P-gp may eventually
prove to be of biological importance extending beyond its
putative role as a cytotoxic drug efflux pump. A key feature
clearly is the widespread distribution of P-gp in normal
tissues, and for cancer therapists this will continue to repre-
sent a therapeutic problem.
To the Cancer Research Campaign for support, and Paul Workman
for useful discussions.
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